Delivering Choices for Heart failure Testing

Abbott provides a choice of heart failure tests, offering both BNP and NT-proBNP biomarkers to aid in diagnosis and assessment of severity of heart failure.

 For in vitro diagnostic use only.

Testing bgd image
Testing bgd image
Testing bgd image

Measuring natriuretic peptides (nps) levels is beneficial in almost every aspect of congestive heart failure care1-5

Abbott’s range of high-performance tests are free from biotin interference and enable identification of levels of Galectin-3 and NP, in combination with clinical assessment, to help define a clinical pathway that improves accurate diagnosis and optimizes patient care.2-9

blue background image
blue background image

Recognizing the complexities of heart failure diagnosis

Heart failure has a complex presentation and can be difficult to diagnose due to non-specific symptoms, such as shortness of breath.10-13
Misdiagnosis can lead to morbidity and in-hospital mortality and re-admission rates are high.11,12

Experimenting image
Experimenting image
Experimenting image

Optimizing diagnosis to tackle the global burden of Heart failure 

 Heart failure results in significant clinical, societal and economic burdens globally. 
More accurate assessment is vital for optimizing resources and improving patient outcomes.14

64.3 million people live with heart failure worldwide15

>1 million hospitalizations in both US and Europe16

1 in 4 patients are re-hospitalized within 30 days.17


44% patients re-hospitalized within 60 days17

Product information


The Alinity i BNP assay is to be used as an aid in the diagnosis and assessment of severity of heart failure.2,3*


The Alere NT-proBNP assay can aid diagnosis of individuals suspected of having congestive heart failure and assessment of heart failure severity.4,5*


The Alinity i Galectin-3 assay can be used in conjunction with clinical evaluation as an aid in assessing the prognosis of patients with chronic heart failure.7

*If BNP or NT-proBNP results are not consistent with other clinical observations, additional information may be required for diagnosis.

Find Out More

Our physician resource provides further information on  how Abbott’s  BNP  and NT-pro BNP  tests aid in the diagnosis and assessment of congestive heart failure.

Experimenting image
Experimenting image
Experimenting image

An accurate reflection of heart failure severity

Both BNP and NT-proBNP levels have been shown to accurately reflect heart failure severity, correlating well with the New York Health Association (NYHA) classification.18  With one diagnostic cut off for all ages, BNP is simpler to interpret. BNP has a narrower clinical grey zone so fewer patients have indeterminate values.12   Patients with heart failure often have renal dysfunction. BNP results are less affected than NT-proBNP by renal dysfunction, as NT-proBNP is solely cleared through the kidneys.12

For BNP, all manufacturers currently suggest a single-decision cut off of 100 pg/mL.12

For NT-proBNP, multiple age-related cut offs are used:4

125 pg/mL < 75 yrs
450 pg/mL ≥ 75 yrs

ICON study recommends several cut offs for NT-proBNP:19 
Rule out:
300 pg/mL
Rule in:
450 pg/mL < 50 yrs
900 pg/mL 50-75 yrs 
1800 pg/mL > 75 yrs


* Age gray zone: age over 50 years or renal dysfunction.
† Clinical gray zone: other non-heart failure conditions may be contributing to elevation.


Adapted from McCullough et al, 2009.


blue background image
blue background image


Understand Risk Stratification

Explore how High Sensitive Troponin can help to more accurately identify your patients' risk of a future cardiac event. 

Cardiac Assays

Instill confidence in your cardiac care decision making with our comprehensive cardiac assay menu.

Visit the Knowledge Center

Find the latest information in laboratory science, therapeutic areas and Abbott innovation.

  1. Pandit K et al. Natriuretic peptides: Diagnostic and therapeutic use. Indian J Endocrinol Metab. 2011;15(Suppl 4):S345–53.
  2. ARCHITECT BNP package insert, (city and state) Abbott Laboratories, (year), 608–-33 10/15/R05.
  3. Alinity BNP reagent package insert, 704-328_R04.
  4. Alere NT-proBNP for ARCHITECT reagent package insert ABBL458/R03.
  5. Alere NT-proBNP for Alinity i Reagent package insert ABBL535/R03.
  6. ARCHITECT Galectin-3 Package Insert. 609-032 8/15/ R05.
  7. Alinity Galectin-3 package insert, 708-325_R01.
  8. McCullough PA et al. Galectin-3: A novel blood test for the evaluation and management of patients with heart failure. Rev Cardiovasc Med. 2011;12(4):200–10.
  9. De Boer RA et al. Galectin-3 in Cardiac Remodeling and Heart Failure. Curr Heart Fail Rep. 2010;7(1):1–8.
  10. Danny C et al. Natriuretic peptides in heart failure. Clin Chem. 2014;60(8):1040–46.
  11. Mueller et al. Cost-effectiveness of B-type natriuretic peptide testing in patients for acute dyspnea. Arch Intern Med. 2006;166(10):1081–87.
  12. McCullough PA, Neyou A. Comprehensive review of the relative clinical utility of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide assays in cardiovascular disease. Open Heart Failure J. 2009;2:6–17.
  1. Ponikowski P et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891–975. 
  2. Lippi et al. Global epidemiology and future trends of heart failure. AME Med J 2020;5:15.
  3. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2018;392:1789–858.
  4. Ambrosy AP et al. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014;63(12):1123–33.
  5. O’Connor CM et al. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program. Am Heart J 2010;159:841–49.
  6. McCullough PA et al. B-type natriuretic peptides: a diagnostic breakthrough for clinicians. Reviews of Cardiovascular Medicine. 2003;4(2):72–80.
  7.  Januzzi JL et. al, N-terminal pro-B-type natriuretic peptide in the emergency department: the ICON-RELOADED study. J Am Coll Cardiol. 2018;71:1191–200.